Genetics of Prostate Cancer in Young Patients (ProK55)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Completed

Conditions: Prostate Carcinoma

Treatments: Genetic: Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT06714227

ProK55

RC 2022-2024 (Other Grant/Funding Number)

Details and patient eligibility

About

The aim of the study is to identify genetic variants in genes responsible or potentially responsible for the etiology of prostate cancer in a population of patients with early onset of the malignancy.

Full description

The data collected from the study will provide a preliminary picture of the prevalence and type of germline pathological variants in the context of early-onset prostate cancer in the Italian population. In addition, alterations in DNA repair genes other than BRCA1-2 and ATM, including any genes yet undescribed as causative or predisposing, have yet to be explored in detail: in many cases the significance of variants is not well defined in terms of pathogenicity, prognostic value, and predictive indicator of response to different treatments. Therefore, an extensive mutational analysis-even if performed on a limited number of patients-can generate a large number of variants for evaluation, bringing knowledge about the relationship between these variants and the onset of malignancy The information obtained, although merely exploratory, may indicate the desirability of conducting systematic genetic investigations in this particular patient population in the future, especially in view of the new therapeutic strategies available such as immunotherapy or PARP inhibitors

Enrollment: 50 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histologic or cytologic diagnosis of prostate cancer
• Age ≥18 years and ≤55 years at first diagnosis of prostate carcinoma
• Availability of clinical and instrumental data related to prostate cancer
• Patients who knowingly express willingness to participate in the study after signing written informed consent

Exclusion criteria

• None

Trial design

50 participants in 1 patient group

Patients diagnosed with prostate carcinoma before the age of 55

Description:

Exome sequencing (WES) of genomic DNA

Treatment:

Genetic: Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample